|Articles|May 11, 2012

Stuart Butler, PhD, Identifies Ways to Approach Cost

Dr. Butler answers why he is not confident that costs will ever be controlled.

Stuart Butler, PhD, Distinguished Fellow and Director, Center for Policy Innovation, The Heritage Foundation, states that the cost curve will never go down on the track we are currently on. Dr. Butler addresses the need for new approaches to bending the curve.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Dr Shannon L. Maude | Image Credit: CHOP

Tisagenlecleucel Yields Promising Disease-Free Survival in High-Risk Pediatric ALL: Shannon L. Maude, MD, PhD

ByBrooke McCormick,Shannon L. Maude, MD, PhD

June 11th 2026

GLP-1 | Image Credit: © Nim9ty Pics-stock.adobe.com.jpeg

Patients on GLP-1s Increasingly Carry Diagnoses for New Indications

ByMaggie L. Shaw

June 11th 2026

Dr Eunice S. Wang | Image Credit: Roswell Park Comprehensive Cancer Center

Ziftomenib Plus 7+3 Yields Strong Responses in NPM1-Mutated, KMT2A-Rearranged AML: Eunice S. Wang, MD

ByBrooke McCormick,Eunice Wang, MD

June 11th 2026

Dr David Kuter | Image Credit: Massachusetts General Hospital

Long-Term Extension Data Support Durable Benefit of Rilzabrutinib in Persistent, Chronic ITP: David Kuter, MD, DPhil

ByBrooke McCormick,David Kuter, MD, DPhil

June 11th 2026

Weight Loss Drugs Can Improve Outcomes in Patients With Heart Failure and Obesity: Sandra Chaparro, MD

ByPearl Steinzor,Sandra Chaparro, MD

June 11th 2026

Stuart Butler, PhD, Identifies Ways to Approach Cost

Related Content

Tisagenlecleucel Yields Promising Disease-Free Survival in High-Risk Pediatric ALL: Shannon L. Maude, MD, PhD

Patients on GLP-1s Increasingly Carry Diagnoses for New Indications

Ziftomenib Plus 7+3 Yields Strong Responses in NPM1-Mutated, KMT2A-Rearranged AML: Eunice S. Wang, MD

Long-Term Extension Data Support Durable Benefit of Rilzabrutinib in Persistent, Chronic ITP: David Kuter, MD, DPhil

Weight Loss Drugs Can Improve Outcomes in Patients With Heart Failure and Obesity: Sandra Chaparro, MD

Trending on AJMC

Special Report: The Oncology Care Model, 10 Years Later

FDA Approves Tocilizumab-bavi for CAR-T-Induced CRS, Pediatric COVID-19

Weight Loss Drugs Can Improve Outcomes in Patients With Heart Failure and Obesity: Sandra Chaparro, MD

AI Model Challenges Genomic Classifiers in Early Breast Cancer Risk Stratification: Nancy Lin, MD

Patients on GLP-1s Increasingly Carry Diagnoses for New Indications